Pallas Health review

Pallas Health, operated by Brentmoor, Inc. out of Newark, Delaware, is the rare cash-pay platform that tells you who makes your medication and who signs your prescription before you hand over a card. Six dispensing pharmacies are named on its clinical page — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — with the 503A and 503B distinction explained rather than glossed. Two physicians are named with their NPI numbers beside a link to look them up: Dr. Ana Lisa Carr, MD (1689841744) and Dr. Kelly Tenbrink, MD (1346482684). Both verify as active in the federal NPPES registry, where Dr. Carr's primary taxonomy is family medicine; the obesity and addiction medicine board certifications the site also claims for her are not verifiable through NPPES and we did not check them independently, so treat those as the site's claim rather than ours. The company is LegitScript Healthcare Merchant Certified, and the price it advertises is the price its checkout charges — which sounds like a low bar until you spend an afternoon in this category. The thing to understand before you start is the billing shape, because it is unusual, and it is averaged rather than hidden. Pallas advertises compounded semaglutide at “$199/mo average” and compounded tirzepatide at “$299/mo average”. Neither is a monthly rate. The funnel renders no cadence selector at all: semaglutide is $139 for the first four weeks and then $597 billed every twelve weeks, tirzepatide is $179 and then $897 on the same schedule, and the advertised averages are those prepay charges divided by three. Two consequences follow from their own published renewal terms. The first is cash flow — after a $139 opening payment, the second charge is $597, in one go, four weeks later. The second is arithmetic: twelve weeks is not three months. A renewal every 84 days recurs 4.35 times a year rather than four, so year one of semaglutide is $139 plus four charges of $597 — $2,527, or about $211 a month — settling near $216 a month thereafter against the $199 on the page. Tirzepatide comes to $3,767 in year one and about $325 a month ongoing against an advertised $299. None of that is concealed, and “twelve weeks ≈ three months” is shorthand the whole industry uses. But the ongoing figure is the one to budget against, and it is why our Budget Fit score here is 43 rather than the mid-60s the headline alone would earn. Cancellation is genuinely easy — a self-serve portal at pallashealth.co/portal, a pre-renewal email reminder, no minimum term, no early-termination fee, thirty days' notice before any price change, and a full refund if a clinician declines you — with two caveats. “Cancel any time” takes effect at the end of a twelve-week block you have already paid for in full, and refunded payments on purchases made from 14 July 2026 have $5 deducted, though never on clinician-declined or unfulfilled orders. Care is asynchronous in 43 states. In Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia and Washington DC a video visit is required, and the $60 deposit for it may be kept if you neither attend nor reschedule and then abandon the intake — otherwise it is refunded in full and credited to your first order. Two disclosures belong on the record. Belmar, one of the six named pharmacies, received an FDA warning letter over compounding practices issued on 31 March 2023 and addressed to Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy; FDA closed that letter out on 30 October 2023. It is a supplier disclosure rather than a mark against Pallas, which has no warning letter of its own — and a provider willing to name six pharmacies is one whose supply chain you can actually check, which is the opposite of this category's usual problem. Separately, the site's own footer states that some of its content is AI-generated with no warranty as to accuracy, so we would not treat anything on its blog as a clinical source; the 4.8 rating it advertises carries no published source and we do not repeat it as a fact; and its before-and-after “Verified Customer” stories note that the individuals shown may be actors or models. Pallas also sells brand-name GLP-1s for cash — Zepbound $1,069/mo, Ozempic $1,299/mo, Wegovy $1,349/mo, Mounjaro $1,349/mo, all genuinely billed monthly — and takes no insurance at any tier, so an insured reader will almost always do better on the brands elsewhere. Compounded semaglutide and tirzepatide are not FDA-approved and are not generic equivalents of those brands; Pallas says so plainly, and so do we. What is not published anywhere: whether baseline or follow-up lab work is included or billed on top, whether the price moves with your dose beyond the site's flat claim (there is no pre-purchase dose selector to check it against), and who prescribes beyond the two named physicians — the wider Lion MD network is not listed, and the footer's “Provider directory” link resolves to the same two doctors. The company launched on our affiliate network on 1 July 2026, so there is no Trustpilot or BBB record to corroborate any of this against yet. Worth choosing if disclosure is the thing you have been unable to find elsewhere and a $597 payment every twelve weeks is one you can absorb without flinching. If you want to pay month to month, or want the option to stop after four weeks having spent four weeks' money, this is not the one.